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Exit-strategies – smart ways to release
phospholipid vesicle cargo†
Denia Mellal and Andreas Zumbuehl*
This highlight describes recent trends in fundamental phospholipid research towards possible future drug
delivery technology. In particular it focuses on synthetic phospholipids and their vesicular constructs and
describes selected “smart” ways to release cargo from liposomes. Various chemical and physical release
triggers are discussed such as temperature changes, application of ultrasound, enzyme degradation,
changes in pH, redox reactions, photochemical reactions, as well as the eﬀects of shear stress on vesicles.
1. Introduction
Liposomes or vesicles are made from one or more concentric
lipid bilayer spheres entrapping an aqueous volume.1 Lipo-
somes can carry drugs in the vesicle’s water cavity, the hydro-
phobic bilayer or attached to the polar lipid surface.1 This
versatility makes liposomes natural drug delivery vehicles and
soon aer the discovery of vesicles2 the rst drugs were encap-
sulated.3 Currently, 13 liposomal drug delivery formulations are
approved by the FDA and a similar number of formulations are
in various stages of clinical trials.3
The volume of a standard liposome with a diameter of
100 nm is surprisingly small: 400 zeptolitres (400  1021 L).4
To put that in relation: a vesicle that was loaded with a 2 mM
solution of doxorubicin5 will optimally contain 500molecules of
the drug.4 If used in a smart fashion, a liposome will therefore
deliver only a limited amount of a drug and will not ush the
human organism with sextillion (1021) copies of a molecule as
we currently do. Through decoration of the outer membrane of
a liposome, vesicles can be kept in the blood circulation for
longer periods of time leading to tumor (outer rim) uptake
through the enhanced permeability and retention eﬀect and
eventual release of the vesicle cargo.3 Besides this passive
approach, it should be possible to actively trigger drug release
from liposomes.6 Here, we could take advantage of the fact that
liposomes are self-assembled from roughly 10 000 molecules4
and that the vesicle composition can easily be modied in the
formulation stage.7 Several possibilities are mentioned in the
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following paragraphs, highlighting the potential of articial
phospholipids (see Fig. 1).
2. Triggered release from liposomes
2.1. Temperature as trigger
Lipid bilayers undergo a gel phase-to-liquid phase transition at
a specic temperature (see Fig. 2 for a schematic overview of the
discussed eﬀects).8 The phase transition (Tm) is inuenced by
the torsional angle found between neighboring CH2 groups in
the n-alkane part of the phospholipids with the gel phase being
represented by an all-anti-periplanar (or all-trans) conformer
and the liquid phase showing several gauche interactions
leading to a reduced alkane packing density.8 At the Tm a
coexistence of gel-phase lipid domains in liquid phase bilayers
is found similar to ice oating in already molten water.9 At the
phase boundaries between solids and liquids, lipid chain
packing defects and therefore lateral density uctuations ensue,
resulting in a maximum of the passive membrane permeability
at the Tm: the membrane becomes leaky.10–12
The Tm not only depends on the lipid chain conformation
but can also be inuenced by the headgroups of the phospho-
lipids with phosphatidylethanolamine (PE) headgroups
showing signicantly higher Tm compared to phosphatidyl-
cholines (PC).8Diﬀerent phospholipids therefore show diﬀerent
passive transbilayer transport characteristics.13 If various
phospholipid types are mixed during vesicle preparation7 the
bilayer Tm can be tuned and diﬀerences in temperature can
then be used as a trigger to release cargo from liposomes.9 A
particularly nice example is a vesicle consisting of
DPPC : HSPC : Chol : DPPE-PEG2000 mixed in a molar ratio of
50 : 25 : 15 : 3 leading to a Tm ¼ 41.9 C.14 In other words: mild
hyperthermia of 42 C will induce drug release. This opens
promising new routes for minimally invasive cancer treatment:
the vesicles were loaded both with a gadolinium-MRI tracer and
the anticancer agent doxorubicin. Using MR-guided
high-intensity focused ultrasound hyperthermia can be
induced locally to deep-seated solid tumors.14
The challenge lies in nding a liposomal system that releases
its cargo rapidly in order to minimize the time a patient needs
to spend in a machine.15 Unfortunately, liposomes will reseal if
the temperature drops below Tm and once more the passive
transbilayer permeability drops signicantly, i.e. the hyper-
thermia conditions need to be maintained for the duration of
the treatment.9 A possible solution to the slow release
mentioned is to simply destroy the vesicular envelope using
lower frequency ultrasound.
2.2. Ultrasound as trigger
High-frequency ultrasound (>1 MHz) mainly leads to thermal
eﬀects as stated in Section 2.1. In contrast, low-frequency
ultrasound has a profound mechanical eﬀect on a bilayer
membrane such as acoustic cavitation.16 An ultrasound wave
will cause the growth and oscillation of a gas bubble leading to
high strain exhibited on the membrane. If the gas nuclei are
formed in the hydrophobic region of a liposomal membrane, it
can lead to transient membrane pore formation and drug
release.16 The eﬀects can be amplied by the presence of lipids
containing unsaturated fatty acyl chains that form less densely
packed bilayers. Furthermore, an eﬀective absorption of ultra-
sound by a phospholipid bilayer membrane is maximized
at the Tm.16
Using HSPC : Chol : DSPE-PEG2000 in a molar ratio of
51 : 44 : 5, it was shown that several types of encapsulated drugs
were almost completely released from the vesicles applying low-
frequency ultrasound for less than 3 minutes.17 The sensitivity
towards ultrasound can be increased by using non-bilayer
forming lipids such as DOPE.18 Additionally, liposomes can
be lled with ultrasound-sensitive emulsions such as per-
uorocarbons.19 Ultrasound will induce a peruorocarbon
Fig. 1 This highlight describes various ways to actively release a cargo
molecule from a phospholipid liposome. The release triggers are either
based on endogenous changes found in the human body (changes in
temperature, enzymatic concentration, pH, redox, and shear stress) or
changes that are applied exogenously (ultrasound or photoreaction
pulses).
Fig. 2 Schematic view of the eﬀects of various release-triggers.
Membrane permeability will be aﬀected if the temperature is raised
above the Tm, if gas bubbles disorder the hydrophobic core of the
membrane, if tails or headgroups are chemically removed from the
phospholipids, if the shapes of phospholipids are changed by reducing
the size of the headgroup or by inducing a signiﬁcant kink in the fatty
tails, and if membrane defects are attenuated by the application of
shear forces. The same conformational and constitutional changes on











phase change from liquid to gaseous and the continued appli-
cation of ultrasound will cause the cavitation of the gas bubble
leading to vesicle membrane disruption.19
2.3. Enzymes as trigger
Roughly half of the phospholipids found in a biomembrane are
prone to induce a lamellar to inverted hexagonal membrane
phase change.20 Such a transition leads to the formation of a
lipidic transmembrane pore. Phosphatidyl ethanolamine
headgroups are less hydrated than their phosphatidyl choline
counterparts. This leads to an increase of the Israelachvili lipid
packing factor and a lipid shape change from cylindrical to
conical.8 The laminar bilayers membrane reacts to this change
by locally inducing an inverted hexagonal phase, i.e. a lipidic
transmembrane channel.
An even more dramatic change can be seen by the action of
phospholipase C on glycerophospholipids leading to diacy-
lglycerols (see Fig. 3 for lipids discussed throughout this text).21
At 37 C one diacylglycerol can inuence the packing of 15
neighbouring phosphatidylcholine or 98 phosphatidylethanol-
amine lipids.22 This number has to be put into relation with the
100 molecules found in an inverted micelle that will ensue,
when diacylglycerols induce a lamellar to inverted hexagonal
membrane phase transition.22 Having phospholipids that are
prone to form inverted hexagonal phases alongside with phos-
pholipids that are forming lamellar phases leads to an equi-
librium that might tilt to either point depending on the ratio
between the lipids.20
The phospholipase PLA2 superfamily includes a broad range
of enzymes dened by their ability to catalyze the hydrolysis of
the ester bond at the sn-2 position of phospholipids, providing a
free fatty acid and a lysolipid, having a cone-shaped packing
factor.8 Therefore, the action of PLA2 on a glycerophospholipid
leads to the formation of pores and is a common pathway of
action of neurotoxins.23 On the other hand, secretory PLA2
enzymes are oen overexpressed in human tumors and the
enzyme might be utilized as a targeted trigger for liposomal
delivery of cancer drugs.24 Interestingly, the incorporation of a
lipopolymer (DPPE-PEG2000) or a short chained DCPC both
signicantly increase the rate of PLA2 action.24
Articial phospholipids were synthesized containing a non-
hydrolyzable ether bond in the sn-1-position and a standard
acyl ester in the sn-2-position. Liposomes formulated from these
lipids were equally prone to PLA2 degradation at sn-2 as their
natural bis-ester counterparts.25 However, the ether-lysolipid
Fig. 3 A selection of “smart”, reactive phospholipids and their triggers. The parts of themolecules that are important for inducing liposome cargo











formed strongly resembles the anti-tumor agent edelfosine.
This lysolipid is highly toxic due to its detergent-like character
once the non-toxic phospholipid is unmasked by enzymatic
action.25,26
Another system used secretory PLA2 sensitive retinoid-
phospholipids for the design of liposomal drug-delivery
systems.27 Here, the lipid backbone of the prodrug contains
either an sn-1-ester or the metabolically more stable sn-1-ether
function. A C6-linker has been incorporated between the glyc-
erol backbone of the lipids and the retinoids to confer more
exibility to the retinoid-phospholipid prodrugs in the sPLA2
active center of the enzyme and thereby enhancing its activity
with a complete prodrug hydrolysis within 24 h.27 Similarly, a-
and d-tocopheryl succinates, two potent cancer cell growth
inhibitors, were linked to the sn-2 position of a phospholipid
backbone.28 Due to their membrane permeability, a non-
covalent incorporation into a liposomal drug delivery system
would not be possible. However, it turned out that the incor-
poration of the tocopherol derivatives made the prodrug a poor
substrate for secretory PLA2-triggered release.28
2.4. pH changes as trigger
The microenvironment of a cancer has a lowered pH value
(pH ¼ 6–7) compared to the healthy surrounding tissue.29,30
Similarly, in the endocytotic pathway of any cell, the pH value
inside the endosomal compartment drops to 6.5 in the early
endosome, 5.0–6.0 in the late endosome, and 4.0–5.0 in the
lysosome.31 Clearly, such changes in proton concentrations that
range over 3 orders of magnitude should be able to serve as a
trigger for liposomal drug delivery. The typical pH-sensitive
liposomal formulations include cone-shaped phospholipids
like DOPE and a weak acid such as cholesteryl hemisuccinate.
However, these formulations loose their fusogenicity in serum,
due to opsonisation. Protection of the liposomal envelope with
a PEG coating seems to signicantly lower the responsiveness of
the system32 and other approaches for pH-sensitive drug
delivery are needed.33
A classic amongst fast-acting pH-labile protecting groups are
orthoesters. They have been cleverly placed as linkers between a
distearoyl glycerol scaﬀold and a polyethylene glycol polymer
headgroup.34 In vitro, the polymer coating is serving as a spacer
between vesicles. Upon hydrolysis of the orthoester, the
unshielded vesicles can come closer to each other and form
inter-membrane stalks leading to lamellar-to-inverted hexag-
onal phase changes and cargo burst release.29 The inter-
membrane contact is essential as initially only 16 molecules
(PEs) on each membrane are involved in stalk formation.22 The
resulting inverted micelle itself initially only contains 100
molecules.22
Vinyl ethers undergo an acid-catalyzed hydrolysis. Incorpo-
rated in low ratios (1–5%) into DOPE liposomes, the vinyl ether
lipids were able to stabilize a lamellar vesicular system until the
vinyl ether bonds were hydrolyzed, leading to the disintegration
of the liposome.35 A signicantly faster reacting system was
found when the acid-labile vinyl ether or ketene acetal bond was
relocated to the lipid headgroup.36 The DOPE : vinyl ether lipid
90 : 10 liposomal mixtures are stable for at least 2 days at pH ¼
7.5 and carry a PEG coating against opsonisation.36 Currently,
they represent one of the most promising triggerable vesicular
drug delivery systems.37
2.5. Redox reactions as trigger
The cytoplasm is a more reducing environment than the blood
plasma.29 This is mainly due to a high sulydryl concentration,
e.g. of glutathione.29 Therefore, dithiol reduction would be a
viable way to release a cone-shaped phospholipid from a
cylindrical precursor molecule. For instance, an ortho-
dithiobenzyl-linked mPEG-DSPE was completely reduced by
cysteine within 30 min.38 This resulted in a 100% release of an
entrapped uorescent marker in 10 min only from a vesicle
formulated from PHPC : cholesterol : dithiol lipid in a molar
ratio of 95 : 5 : 3.38
In combination with the enhanced permeability and reten-
tion eﬀect, liposomes could be exposed to the upregulated
quinone reductase enzyme found near cancerous tissue.39
Therefore, a quinone phospholipid was synthesized that, upon
reduction of the quinone to a hydroquinone, would undergo a
cascade reaction to set free a molecule of DOPE.39 The formu-
lated vesicles were stable for at least a week, and, as expected,
upon dithionite reduction the entrapped calcein was released in
about 5 hours.39 An improved formulation including DOPE and
small amounts (#3%) PEG2000-DOPE signicantly shortened
the cargo release to 30 min only.40
2.6. Photo-reactions as trigger
Light can be used in three diﬀerent ways in order to release a
cargo from phospholipid vesicles: lipids can be uncaged, poly-
merized, or they can undergo trans/cis isomerization.41 This
leads to an interesting liposomal toolbox for topical applica-
tions (due to the low tissue penetration of light) and mainly
biochemical applications.6,42
The use of photocleavable amine protecting groups is an
attractive means to mask the headgroup of a PE phospholipid
and inducing a lamellar phase preference of the molecule.43 The
irradiation of 6-nitroveratryloxycarbonyl protected lipid with a
150 W UV light lead to an 90% deprotection of the amine in
20 min.43 Applied to a vesicular system, a beautiful rst order
rate release of entrapped calcein was noted, unfortunately its
applications are limited due to photobleaching eﬀects.
The light-triggered activation of polymerizable phospho-
lipids leads to solid domains within liquid phospholipid
membranes. Similar to the temperature eﬀects seen in Section
2.1, this translates into increasedmembrane permeability at the
phase boundaries.41 When a liposomal formulation of choles-
terol : bis-SorbPC : DOPC : PEG200-DOPE in a molar ratio of
40 : 30 : 15 : 15 was exposed to UV light for 5 min, the bis-
SorbPC was completely polymerized and this leads to a
200-fold increase of membrane permeability for water-soluble
compounds.44 Diacetylene lipids such as (DC8,9PC) are clas-
sical polymerizable phospholipids.45 DPPC : DC8,9PC vesicles
were formulated at a molar ratio of 86 : 10 and loaded with











514 nm for 5 min which resulted in half of the cells being killed
in this short period of time.46
Bis-azo phospholipids undergo wavelength-dependent trans/
cis isomerization under UV light. This transition has a direct
inuence on membrane packing.47 Indeed, DPPC : cholester-
ol : bis-azoPC formulations at amolar ratio of 69 : 25 : 6 showed
an complete loss of entrapped calcein when exposed to light at
470 nm for 30 seconds.48 In a follow-up study it was shown that
cargo-release could be triggered even by a single (10 ns!) laser
pulse.49
An additional release pathway leads through the incorpora-
tion of a non-lipidic photosensitizer into the liposomal
membrane such as trisulfonated aluminum phthalocyanine50 or
aluminum phthalocyanine disulfonic acid51 leading to a singlet-
oxygen mediated oxidation of lipid double bonds and contin-
uous release of cargo molecules.51
2.7. Shear stress as trigger
The diﬀerences in shear-stresses in the human body could be
used as a drug delivery trigger, as has been reported very
recently.52,53 This purely physical trigger is interesting in situa-
tions where biological targeting is not viable, e.g. in the case of
atherosclerosis where the inammation signals of the plaque
are not diﬀerent from other inammation signals found in the
body.54 On the other hand, standard wall-shear stresses
measured in the blood stream are around 1.5 Pa and rise more
than one order of magnitude close and at the site of a blood
vessel constriction.55
In order to use phospholipid vesicles as shear-sensitive drug
delivery devices, two major obstacles must be overcome. First,
spherical vesicles will only shear at around 40 Pa, a value that is
too high for in vivo applications; this calls for non-spherical,
faceted particles.56,54 Second, a vesicle formulation is needed
that is not-releasing its cargo when at rest but releases its
contents when shaken. Natural phospholipid vesicles are either
leaky in both cases (eggPC) or do not release in both cases
(DPPC or 16:0 SM).52
Recently, faceted self-assembly systems based on catanionic
lipids have gained signicant interest in the so matter
community.57,58 The combination of a high bilayer stretching
energy and a lower bending energy leads to a high Fo¨ppl–van-
Ka`rma`n ratio and the formation of non-spherical particles.59 A
synthetic 1,3-diamidophospholipid, Pad-PC-Pad, has been
reported where the fatty acyl tails are spaced in the non-natural
1,3-fashion compared to the natural 1,2-constitution.60 This
possibly leads to easier membrane leaet interdigitation, which
would impose a high bilayer stiﬀness.61 Indeed, vesicles
formulated from Pad-PC-Pad are non-spherical and show a
lenticular morphology.52
Vesicles formulated from pure Pad-PC-Pad were not
releasing the entrapped 5(6)-carboxyuorescein when le
untouched on the bench. As soon as the vesicles were shaken,
either by hand or by vortex shaker, 40% of the cargo was
released within one minute.52 Additionally, in vitro assays
showed a signicant diﬀerence of vesicle cargo release when the
liposomes were exposed to an articial blood circulation con-
taining either a “healthy” or “stenosed” plastic artery model.52
3. Conclusions
During the past years, chemical lipidology has led to a large
variety of synthetic phospholipids. Each of these lipids was
formulated into vesicles that reacted to diﬀerent external
stimuli, signicantly enhancing the potential of liposomal drug
delivery. The power of the vesicles lies in the self-assembly
approach that allows for simple mixing of diﬀerent non-toxic
liposome components. Through the synthesis of additional
types of phospholipids, a new generation of “smart” vesicles
becomes accessible, and hopefully will have an impact as future
delivery tools in biology and medicine.
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